🇺🇸 spironolactone + furosemide in United States
75 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 75
Most-reported reactions
- Hyperkalaemia — 10 reports (13.33%)
- Renal Failure Acute — 10 reports (13.33%)
- Renal Failure — 8 reports (10.67%)
- Cardiac Failure — 7 reports (9.33%)
- Confusional State — 7 reports (9.33%)
- Dehydration — 7 reports (9.33%)
- Drug Interaction — 7 reports (9.33%)
- Fall — 7 reports (9.33%)
- Anaemia — 6 reports (8%)
- Dyspnoea — 6 reports (8%)
Other Cardiovascular approved in United States
Frequently asked questions
Is spironolactone + furosemide approved in United States?
spironolactone + furosemide does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for spironolactone + furosemide in United States?
Tottori University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.